Vrije Universiteit Brussel

 

Publications on Multiple Myeloma

  • Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation.
    De Beule N, De Veirman K, Maes K, De Bruyne E, Menu E, Breckpot K, De Raeve H, Van Rampelbergh R, Van Ginderachter JA, Schots R, Van Valckenborgh E, Vanderkerken K..
    J Pathol. 2017
    241(4):534-546.

  • The myeloma stem cell concept, revisited: from phenomenology to operational terms.
    Johnsen HE, Bøgsted M, Schmitz A, Bødker JS, El-Galaly TC, Johansen P, Valent P, Zojer N, Van Valckenborgh E, Vanderkerken K, van Duin M, Sonneveld P, Perez-Andres M, Orfao A, Dybkær K.
    Haematologica 2016
    241(4):534-546.

  • Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma.
    Wang J, Faict S, Maes K, De Bruyne E, Van Valckenborgh E, Schots R, Vanderkerken K, Menu E.
    Oncotarget 2016
    241(4):534-546.

  • A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement.
    Rasche L, Menoret E, Dubljevic V, Menu E, Vanderkerken K, Lapa C, Steinbrunn T, Chatterjee M, Knop S, Düll J, Greenwood DL, Hensel F, Rosenwald A, Einsele H, Brändlein S..
    Clin Cancer Res 2016
    241(4):534-546.

  • Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity.
    De Veirman K, Wang J, Xu S, Leleu X, Himpe E, Maes K, De Bruyne E, Van Valckenborgh E, Vanderkerken K, Menu E, Van Riet I. .
    Cancer Letters 2016
    377(1):17-24

  • SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma
    Heusschen R, Muller J, Binsfeld M, Marty C, Plougonven E, Dubois S, Mahli N, Moermans K, Carmeliet G, Léonard A, Baron F, Beguin Y, Menu E, Cohen-Solal M, Caers J. .
    Oncotarget 2016
    7(21):30712-29

  • Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?
    Favreau M, Vanderkerken K, Elewaut D, Venken K, Menu E. .
    Oncotarget 2016
    7(17):23128-40

  • Abnormal IGF-Binding Protein profile in the bone marrow of multiple myeloma patients.
    Bieghs L, Brohus M, Kristensen I, Abilgaard N, Boegsted M.
    PloS One 2016
    11:e0154256

  • The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential.
    Bieghs L, Hans J, Maes K, Menu E, Van Valckenborgh E, Overgaard MT, Nyegaard M, Conover C, Vanderkerken K, De Bruyne E. .
    Oncotarget 2016
    7(30):48732- 48752

  • Multiple myeloma exosomes establish a favorable bone marrow microenvironment with enhanced angiogenesis and immunosuppression
    Wang J, De Veirman K, Faict S, Frassanito MA, Ribatti D, Vacca A, Menu E.
    J og Pathology 2016
    239(2):162-73

  • Halting pro-survival autophagy by TGFß inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients. Leukemia.
    Frassanito A, De Veirman K, Desantis V, Marzo L, Vergara D, Ruggieri S, Annese T, Nico B, Menu E, Catacchio I, Ria R, Racanelli V, Maffia M, Angelucci E, Derudas D, Fumarulo R, Dammacco F, Ribatti D, Vanderkerken K, Vacca A. .
    Leukemia 2016
    30(3):640-648

  • Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy
    Dufait I, Van Valckenborgh E, Menu E, Escors D, De Ridder M, Breckpot K. .
    Oncotarget 2016

  • Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma.
    Wang J, Faict S, Maes K, De Bruyne E, Van Valckenborgh E, Schots H, Vanderkerken K. Menu E. .
    Oncotarget 2016
    7(25): 38927-38945

  • Novel strategies to target the ubiquitin proteasome system in multiple myeloma.
    Lub S, Maes K, Menu E, De Bruyne E, Vanderkerken K, Van Valckenborgh E.
    Oncotarget 2016
    7(6):6521-6537

  • Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells.
    Lub S, Maes A, Maes K, De Veirman K, De Bruyne E, Menu E, Fostier K, Kassambara A, Moreaux J, Hose D, Leleu X, King RW, Vanderkerken K, Van Valckenborgh E. .
    Oncotarget 2016
    7(4):4062-4076

  • The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.
    Wang J, De Veirman K, De Beule N, Maes K, De Bruyne E, Van Valckenborgh E, Vanderkerken K, Menu E. .
    Oncotarget 2015
    6(41):43992-44004

  • Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche.
    Lawson MA, McDonald MM, Kovacic N, Hua Khoo W, Terry RL, Down J, Kaplan W, Paton-Hough J, Fellows C, Pettitt JA, Neil Dear T, Van Valckenborgh E, Baldock PA, Rogers MJ, Eaton CL, Vanderkerken K, Pettit AR, Quinn JM, Zannettino AC, Phan TG, Croucher PI. .
    Nat.Commun. 2015
    6:8983.

  • Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2 - implications for a combinatorial treatment.
    Duvefelt CF, Lub S, Agarwal P, Arngården L, Hammarberg A, Maes K, Van Valckenborgh E, Vanderkerken K, Jernberg-Wiklund H..
    Oncotarget 2015
    6(24):20621-35

  • Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells.
    De Veirman K, Van Ginderachter JA, Lub S, De Beule N, Thielemans K, Bautmans I, Oyajobi BO, De Bruyne E, Menu E, Lemaire M, Van Riet I, Vanderkerken K, Van Valckenborgh E. .
    Oncotarget 2015
    6(12):10532-47

  • Myeloid-derived suppressor cells as therapeutic target in hematological malignancies.
    De Veirman K, Van Valckenborgh E, Lahmar O, Geeraerts X, De Bruyne E, Menu E, Van Riet I, Vanderkerken K, Van Ginderachter J. .
    Front Oncol. 2014
    4:349.

  • Tumor-initiating capacity of CD138- and CD138+ tumor cells in the 5T33 multiple myeloma model.
    Van Valckenborgh E, Matsui W, Agarwal P, Lub S, Dehui X, De Bruyne E, Menu E, Empsen C, van Grunsven L, Agarwal J, Wang Q, Jernberg-Wiklund H, Vanderkerken K.
    Leukemia. 2012 Jan 6.

  • Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition.
    Hu J, Dang N, Menu E, De Bryune E, Xu D, Van Camp B, Van Valckenborgh E, Vanderkerken K.
    Blood. 2012 Jan 19;119(3):826-37. Epub 2011 Nov 29.

  • Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study.
    Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, Leleu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG; on behalf of the International Myeloma Working Group; International Myeloma Working Group, Abildgaard N, Abonour R, Alexanian R, Alsina M, Anderson KC, Attal M, Avet-Loiseau H, Badros A, Baris D, Barlogie B, Bataille R, Beksaç M, Belch A, Ben-Yehuda D, Bensinger B, Leif Bergsagel P, Bird J, Bladé J, Boccadoro M, Cavo M, Chanan-Khan A, Ming Chen W, Child T, Chim J, Chng WJ, Comenzo R, Crowley J, Dalton W, Davies F, de Souza C, Delforge M, Dimopoulos M, Dispenzieri A, Drach J, Drake M, Durie BG, Einsele H, Facon T, Fantl D, Fermand JP, Fonseca R, Gahrton G, García-Sanz R, Gasparetto C, Gertz M, Gibson J, Giralt S, Goldschmidt H, Greipp P, Hajek R, Hardan I, Hari P, Harousseau JL, Hata H, Hattori Y, Heffner T, Ho J, Hungria V, Ida S, Jacobs P, Jagannath S, Johnsen H, Jian H, Joshua D, Jurczyszyn A, Kawano M, Kröger N, Kumar S, Kyle RA, Lacy M, Lahuerta JJ, Landgren O, Laubach J, Lee JH, Leleu X, Lentzsch S, Lokhorst H, Lonial S, Ludwig H, Maiolino A, Mateos M, Mehta J, Mellqvist UH, Merlini G, Mikhael J, Morales AR, Moreau P, Morgan G, Nari H, Munshi N, Niesvizky R, Nouel A, Novis Y, Orlowski R, Palumbo A, Pavlovsky S, Pilarski L, Powles R, Raje N, Vincent Rajkumar S, Reece D, Reiman T, Richardson PG, Roodman D, Rosiñol L, Miguel JS, Sezer O, Shah JJ, Shaughnessy J, Shimizu K, Shustik C, Siegel D, Singhal S, Sonneveld P, Spencer A, Stadtmauer E, Stewart K, Terpos E, Tosi P, Tricot G, Turesson I, Van Camp B, Van Ness B, Van Riet I, Broek IV, Vanderkerken K, Vescio R, Vesole D, Waage A, Wang M, Weber D, Westin J, Wheatley K, Zonder J. .
    Leukemia-2011 .
    Abstract.

  • Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.
    Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, Ludwig H, Joshua D, Mehta J, Gertz M, Avet-Loiseau H, Beksaç M, Anderson KC, Moreau P, Singhal S, Goldschmidt H, Boccadoro M, Kumar S, Giralt S, Munshi NC, Jagannath S; International Myeloma Workshop Consensus Panel 3. (Raje N, Comenzo RL, Sezer O, Hussein M, Jelinek DF, Tricot G, Badros A, Powles RL, Blade J, Kroger N, Waage A, Durie B, David Roodman G, Niesvizky R, Nouel A, Vesole DH, Rodriguez A, Schots R, Merlini G, Zangari M, Weber DM, Zonder J, Kawano MM, Greipp PR, Chandy M, Van Ness B, Treon S, Klein LM, Vinod R.) .
    Blood.-2011 .
    Abstract.

  • Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.
    Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, Fonseca R, Stewart AK, Harousseau JL, Dimopoulos M, Jagannath S, Hajek R, Sezer O, Kyle R, Sonneveld P, Cavo M, Rajkumar SV, San Miguel J, Crowley J, Avet-Loiseau H; International Myeloma Workshop Consensus Panel 2.(Kumar S, Siegel DS, Moreau P, Einsele H, Singhal S, Ghobrial IM, Gharton G, Berenson JR, Mehta J, Dispenzieri A, Lonial S, Niesvizky R, Schlossman R, Vesole DH, Chanan-Khan A, Wolf J, Kuehl M, Drach J, Schots R, Merlini G, Zangari M, Zonder J, Thompson Heffner L Jr, Garcia Sanz R, Greipp PR, Raina V.) .
    Blood. -2011 .
    Abstract.

  • Recent advances in myeloma treatment.
    Schots R. .
    Transfus Apher Sci. -2011 .
    Abstract.

  • Tumor-promoting properties of bone marrow-derived mesenchymal stem cells (MSCs) in multiple myeloma (MM): a potential risk for MSC-based cytotherapy in MM patients?
    Xu S, Menu E, De Becker A, Van Camp B, Vanderkerken K, Van Riet I .
    Stem Cells-2011 .
    Abstract.

  • The microenvironment and molecular biology of the multiple myeloma tumor.
    Lemaire M, Deleu S, De Bruyne E, Van Valckenborgh E, Menu E, Vanderkerken K. .
    Adv Cancer Res-2011 .
    Abstract.

  • Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo.
    Chantry AD, Heath D, Mulivor AW, Pearsall S, Baud'huin M, Coulton L, Evans H, Abdul N, Werner ED, Bouxsein ML, Key ML, Seehra J, Arnett TR, Vanderkerken K, Croucher P .
    J Bone Miner Res-2010 .
    Abstract.

  • In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2.
    Maes K, Nemeth E, Roodman GD, Huston A, Esteve F, Freytes C, Callander N, Katodritou E, Tussing-Humphreys L, Rivera S, Vanderkerken K, Lichtenstein A, Ganz T. .
    Blood-2010 .
    Abstract.

  • The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group.
    Terpos E, Dimopoulos MA, Sezer O, Roodman D, Abildgaard N, Vescio R, Tosi P, Garcia-Sanz R, Davies F, Chanan-Khan A, Palumbo A, Sonneveld P, Drake MT, Harousseau JL, Anderson KC, Durie BG; International Myeloma Working Group. (Abonour R, Alexanian R, Anderson KC, Attal M, Avet-Loiseau H, Badros A, Barlogie B, Batille R, Beksac M, Belch A, Bensinger B, Bergsagel PL, Bird J, Bladé J, Boccadoro M, Cavo M, Chen WM, Child T, Chim J, Chng WJ, Comenzo R, Crowley J, Dalton W, Davies F, de Souza C, Delforge M, Dimopoulos M, Dispenzieri A, Drake M, Durie BG, Drach J, Einsele H, Faco T, Fantl D, Fermand JP, Fonseca R, Gahrton G, Gasparetto C, Gertz M, Gibson J, Giralt S, Goldschmidt H, Greipp P, Hajek R, Hardan I, Harousseau JL, Hata H, Hattori Y, Heffner T, Ho J, Hungria V, Ida S, Jacobs P, Jagannath S, Jian H, Joshua D, Jurczyszyn A, Kahn AC, Kawano M, Kröger N, Kumar S, Kyle R, Lahuerta J, Landgren O, Laubach J, Lee JH, LeLeu X, Lentzsch S, Lokhorst H, Lonial S, Ludwig H, Maiolino A, Mateos M, Mehta J, Merlini G, Mikhael J, Morales AR, Moreau P, Morgan G, Munshi N, Niesvizky R, Nouel A, Novis Y, Orlowski R, Palumbo A, Pavlovsky S, Pilarski L, Powles R, Rajkumar SV, Reece D, Reiman T, Richardson PG, Roodman D, Rosinol L, San Miguel J, Sezer O, Shah J, Shaughnessy J, Shimizu K, Shustik C, Siegel D, Singhal S, Sonneveld P, Spencer A, Stadtmauer E, Stewart K, Terpos E, Tosi P, Tricot G, Turesson I, Vanderkerken K, Van Ness B, Van Riet I, Vescio R, Vesole D, Waage A, Wang M, Weber D, Westin J, Wheatley K, Yehuda DB, Zonder J.) .
    Leukemia.-2010 .
    Abstract.

  • Large double copy vectors are functional but show a size-dependent decline in transduction efficiency.
    Bos TJ, De Bruyne E, Van Lint S, Heirman C, Vanderkerken K. .
    J Biotechnol-2010 .
    Abstract.

  • Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.
    Hu J, Handisides DR, Van Valckenborgh E, De Raeve H, Menu E, Vande Broek I, Liu Q, Sun JD, Van Camp B, Hart CP, Vanderkerken K. .
    Blood.-2010 .
    Abstract.

  • The Belgian 2010 consensus recommendations for the treatment of multiple myeloma.
    Schots R, Delforge M, André M, Bries G, Caers J, Demuynck H, De Prijck B, De Samblanx H, Kentos A, Meuleman N, Offner F, Vekemans MC, Vande Broek I, Van Droogenbroeck J, Van de Vanelde A, Wu KL, Doyen C; Multiple Myeloma Study Group of the Belgian Hematological Society. .
    Acta Clin Belg-2010 .
    Abstract.

  • Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.
    Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kröger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M; International Myeloma Working Group. (Alexanian R, Attal M, Badros A, Baris D, Batille R, Beksac M, Belch A, Bensinger B, Bergsagel PL, Bird J, Cavo M, Chanan-Khan A, Child T, Chim J, Chng W-J, Comenzo R, Crowley J, Dalton W, Davies F, de Souza C, Delforge M, Dispenzieri A, Drach J, Facon T, Fantl D, Fermand J-P, Fonseca R, Gahrton G, Garcia-Sanz R, Gasparetto C, Gertz M, Gibson J, Giralt S, Goldschmidt H, Hardan I, Harousseau J-L, Hata H, Hattori Y, Heffner T, Ho J, Hungria V, Ida S, Jacobs P, Jagannath S, Jian H, Joshua D, Jurczyszyn A, Kawano M, Kumar S, Lahuerta J, Laubach J, Lee JH, LeLeu X, Lentzsch S, Lokhorst H, Lonial S, Maiolino A, Mateos M, Mehta J, Mellqvist U-F, Mikhael J, Rodriquez Morales A, Moreau P, Morgan G, Munshi N, Niesvizky R, Nouel A, Novis Y, Orlowski R, Pilarski L, Powles R, Reece D, Reiman T, Roodman D, Rosinol L, Sezer O, Shah JJ, Shaughnessy J, Shimizu K, Shustik C, Siegel D, Singhal S, Spencer A, Stadtmauer E, Stewart K, Terpos E, Tosi P, Tricot G, Vanderkerken K, Van Ness B, Van Riet I, Waage A, Wang M, Weber D, Wheatley K, Yehuda DB, Zonder J.) .
    Leukemia-2010 .
    Abstract.

  • Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
    Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Esseltine DL, Liu K, Cakana A, van de Velde H, San Miguel JF. .
    J Clin Oncol. -2010 .
    Abstract.

  • The effects of forodesine in murine and human multiple myeloma cells.
    Bieghs L, Caers J, De Bruyne E, Van Valckenborgh E, Higginbotham F, Vanderkerken K, Menu E. .

    Adv Hematol-2010 .
    Abstract.

  • IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms.
    De Bruyne E, Bos TJ, Schuit F, Van Valckenborgh E, Menu E, Thorrez L, Atadja P, Jernberg-Wiklund H, Vanderkerken K .
    2010 Mar 25;115(12):2430-40. Epub 2010 Jan 19 .
    Abstract.

  • Thymosin beta4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma.
    Caers J, Hose D, Kuipers I, Bos TJ, Van Valckenborgh E, Menu E, De Bruyne E, Goldschmidt H, Van Camp B, Klein B, Vanderkerken K. .
    Haematologica. 2010 Jan;95(1):163-7. Epub 2009 Oct 14. .
    Abstract.

  • Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.
    Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, Vande Broek I, De Raeve H, Coulton L, Van Camp B, Croucher P, Vanderkerken K. .
    Cancer Res. 2009 Jul 1;69(13):5307-11. Epub 2009 Jun 16. .
    Abstract.

  • In search of the most suitable lentiviral shRNA system.
    Bos TJ, De Bruyne E, Heirman C, Vanderkerken K. .
    Curr Gene Ther. 2009 Jun;9(3):192-211. Review. .
    Abstract.

  • The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models.
    Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, King P, Vande Broek I, De Raeve H, Van Camp B, Croucher P, Vanderkerken K. .
    Leukemia. 2009 Oct;23(10):1894-903. Epub 2009 Jun 4 .
    Abstract.

  • The role of the insulin-like growth factor 1 receptor axis in multiple myeloma.
    Menu E, van Valckenborgh E, van Camp B, Vanderkerken K. .
    Arch Physiol Biochem. 2009 May;115(2):49-57. Review. .
    Abstract.

  • VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with Multiple Myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the Phase III VISTA Study
    Dimopoulos MA, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kastritis E, Kropff M., Petrucci MT, Delforge M., Alexeeva J, Schots R, Masszi T, Mateos MV, Deraedt W, Liu K., Cakana A., Van De Velde H., San Miguel JF. .
    Journal of Clinical Oncology-2009 .
    Abstract.

  • International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
    Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BG; International Myeloma Working Group. Collaborators: Alexanian R, Anderson K, Attal M, Avet-Loiseau H, Badros A, Bergsagel L, Blade J, Barlogie B, Batille R, Beksac M, Belch A, Bensinger B, Boccadoro M, Cavo M, Chen WM, Child T, Chim J, Comenzo R, Crowley J, Dalton W, Davies F, de Souza C, Delforge M, Dimipoulous M, Dispenzieri A, Einsele H, Facon T, Fantl D, Fermand JP, Fonseca R, Gahrton G, Gertz M, Gibson J, Goldschmidt H, Greipp P, Hajek R, Hardan I, Harousseau JL, Hata H, Hattori Y, Ho J, Hungria V, Hussein M, Ida S, Jacobs P, Jagannath S, Jian H, Joshua D, Kawano M, Kumar S, Kyle R, Lahuerta J, Lee JH, Lokhorst H, Ludwig H, LeLeu X, Maiolino A, Mehta J, Merlini G, Moreau P, Morgan G, Munshi N, Palumbo A, Pavlovsky S, Niesvizky R, Novis Y, Nouel A, Powles R, Pilarski L, Rajkumar SV, Reece D, Reiman T, Richardson P, Rodriquez A, Sezer O, Shaughnessy J, Shimizu K, Siegel D, Tricot G, San Miguel J, Singhal S, Sonneveld P, Shustik C, Spencer A, Stewart K, Tosi P, Turesson I, Van Ness B, Van Riet I, Vescio R, Vesole D, Waage A, Wang M, Weber D, Westin J, Wheatley K, Yehuda DB, Zonder J. .
    Leukemia-2009 .
    Abstract.

  • Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
    Sonneveld P, Hajek R, Nagler A, Spencer A, Bladé J, Robak T, Zhuang SH, Harousseau JL, Orlowski RZ; DOXIL-MMY-3001 Study Investigators. .
    Cancer-2008 .
    Abstract.

  • The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement.
    Hussein MA, Vrionis FD, Allison R, Berenson J, Berven S, Erdem E, Giralt S, Jagannath S, Kyle RA, LeGrand S, Pflugmacher R, Raje N, Rajkumar SV, Randall RL, Roodman D, Siegel D, Vescio R, Zonder J, Durie BG; International Myeloma Working Group.Collaborators: Alexanian R, Anderson K, Attal M, Avet-Loiseau H, Badros A, Bergsagel L, Bladé J, Barlogie B, Batille R, Beksac M, Belch A, Bensinger B, Boccadoro M, Cavo M, Chen WM, Child T, Chim J, Comenzo R, Crowley J, Dalton W, Davies F, de Souza C, Delforge M, Dimipoulous M, Dispenzieri A, Einsele H, Facon T, Fantl D, Fermand JP, Fonseca R, Gahrton G, Gertz M, Gibson J, Goldschmidt H, Greipp P, Hajek R, Hardan I, Harousseau JL, Hata H, Hattori Y, Ho J, Hungria V, Hussein M, Ida S, Jacobs P, Jagannath S, Jian H, Joshua D, Kawano M, Kumar S, Kyle R, Lahuerta J, Lee JH, Lokhorst H, Ludwig H, LeLeu X, Maiolino A, Mehta J, Merlini G, Moreau P, Morgan G, Munshi N, Palumbo A, Pavlovsky S, Niesvizky R, Novis Y, Nouel A, Powles R, Pilarski L, Rajkumar SV, Reece D, Reiman T, Richardson P, Morales AR, Sezer O, Shaughnessy J, Shimizu K, Siegel D, Tricot G, San Miguel J, Singhal S, Sonneveld P, Shustik C, Spencer A, Stewart K, Tosi P, Turesson I, Van Ness B, Van Riet I, Vescio R, Vesole D, Waage A, Wang M, Weber D, Westin J, Wheatley K, Yehuda DB, Zonder J .
    Leukemia.-2008 .
    Abstract.

  • Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
    San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, Van De Velde H, Richardson PG .
    N Engl J Med-2008 .
    Abstract.

  • Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study.
    Bourhis J-H, Bouko Y, Koscielny S, Bakkus M, Greinix H, Derigs G, Salles G, Feremans W, Apperley JF, Samson D, Bjôrkstrand B, Niederwieser D, Gahrton G, Pico J-L, Goldschmidt H. .
    Haematologica / the Haematology Journal-2007 .
    Abstract.

  • Extramedullary plasmacytoma of the cavernous sinus.
    Vande Broek I, Stadnik T, Meurs A, Maes J, Van Camp B, Schots R. .
    Leuk Lymphoma-2002 .
    Abstract.

  • Diagnostic and prognostic value of the MB2 monoclonal antibody in paraffin-embedded bone marrow sections of patients with multiple myeloma and monoclonal gammopathy of undetermined significance.
    Dehou MF, Schots R, Lacor P, Arras N, Verhavert P, Klöppel G, van Camp B. .
    Am J Clin Pathol-1990 .
    Abstract.

  • Polycomb target genes are silenced in multiple myeloma.
    Kalushkova A, Fryknäs M, Lemaire M, Fristedt C, Agarwal P, Eriksson M, Deleu S, Atadja P, Osterborg A, Nilsson K, Vanderkerken K, Oberg F, Jernberg-Wiklund H. .
    PLoS One. 2010 Jul 9;5(7):e11483.PMID: 20634887
    Abstract.

  • Thymosin beta4 in multiple myeloma: friend or foe.
    Caers J, Otjacques E, Hose D, Klein B, Vanderkerken K. .
    Ann N Y Acad Sci. 2010 Apr;1194:125-9. Review.PMID: 20536459
    Abstract.

  • IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms.
    De Bruyne E, Bos TJ, Schuit F, Van Valckenborgh E, Menu E, Thorrez L, Atadja P, Jernberg-Wiklund H, Vanderkerken K .
    2010 Mar 25;115(12):2430-40. Epub 2010 Jan 19 .
    Abstract.

  • Thymosin beta4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma.
    Caers J, Hose D, Kuipers I, Bos TJ, Van Valckenborgh E, Menu E, De Bruyne E, Goldschmidt H, Van Camp B, Klein B, Vanderkerken K. .
    Haematologica. 2010 Jan;95(1):163-7. Epub 2009 Oct 14. .
    Abstract.

  • Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.
    Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, Vande Broek I, De Raeve H, Coulton L, Van Camp B, Croucher P, Vanderkerken K. .
    Cancer Res. 2009 Jul 1;69(13):5307-11. Epub 2009 Jun 16. .
    Abstract.

  • In search of the most suitable lentiviral shRNA system.
    Bos TJ, De Bruyne E, Heirman C, Vanderkerken K. .
    Curr Gene Ther. 2009 Jun;9(3):192-211. Review. .
    Abstract.

  • The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models.
    Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, King P, Vande Broek I, De Raeve H, Van Camp B, Croucher P, Vanderkerken K. .
    Leukemia. 2009 Oct;23(10):1894-903. Epub 2009 Jun 4 .
    Abstract.

  • The Role of Insulin-like Growth Factor 1 Receptor Axis in Multiple Myeloma.
    Menu E, Valckenborgh EV, Camp BV, Vanderkerken K.
    Arch Physiol Biochem [Epub ahead of print] (Feb 21), 1-9, 2009.
    Abstract.

  • Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma.
    Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy JD, Evans HR, Snowden JA, Stover DR, Vanderkerken K, Croucher PI.
    J Bone Miner Res 24 (3), 425-36, 2009.
    Abstract.

  • Screening of Trichostatin Analogues Based on Cellular Potency in the Murine Multiple Myeloma 5T33MM Model.
    Deleu S, Fraczek J, Lukaszuk A, Doktorova T, Tourwe D, Geerts A, Van Camp B, Vanhaecke T, Rogiers V, Vanderkerken K.
    J Cancer Mol 4, 117-121, 2008.
    Abstract.

  • Geranylgeranyl Transferase Type II Inhibition Prevents Myeloma Bone Diseases.
    Lawson MA, Coulton L, Ebetino FH, Vanderkerken K, Croucher PI.
    Biochem Biophys Res Commun 377 (2), 453-457, 2008.
    Abstract.

  • Screening of Amide Analogues of Trichostatin A in Cultures of Primary Rat Hepatocytes: Search for Potent and Safe HDAC Inhibitors.
    Fraczek J, Deleu S, Lukaszuk A, Doktorova T, Tourwe D, Geerts A, Vanhaecke T, Vanderkerken K, Rogiers V.
    Invest New Drugs Sep 30 ([Epub ahead of print]), , 2008.
    Abstract.

  • Multiple Myeloma, an update on diagnosis and treatment.
    Caers J, Vande Broek I, De Raeve H, Michaux L, Trullemans F, Schots R, Van Camp B, Vanderkerken K.
    Eur J Haematol Jul 11 ([Epub ahead of print]), , 2008.
    Abstract.

  • A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.
    Menu E, Garcia J, Huang X, Di Liberto M, Toogood PL, Chen I, Vanderkerken K, Chen-Kiang S.
    Cancer Res 68 (14), 5519-23, 2008.
    Abstract.

  • Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
    San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG, VISTA Trial Investigators.
    N Engl J Med 359 (9), 906-17, 2008.
    Abstract.

  • Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma.
    Caers J, Menu E, De Raeve H, Lepage D, Van Valckenborgh E, Van Camp B, Alvarez E, Vanderkerken K.
    Br J Cancer 98 (12), 1966-74, 2008.
    Abstract.

  • Epigenetic Silencing of the Tetraspanin CD9 during Disease Progression in Multiple Myeloma Cells and Correlation with Survival.
    De Bruyne E, Bos TJ, Asosingh K, Vande Broek I, Menu E, Van Valckenborgh E, Atadja P, Coiteux V, Leleu X, Thielemans K, Van Camp B, Vanderkerken K, Van Riet I.
    Clin Cancer Res 14 (10), 2918-26, 2008.
    Abstract.

  • Unraveling the biology of multiple myeloma disease: cancer stem cells acquired intracellular changes and interactions with the surrounding microenvironment.
    Caers J, Van Valckenborgh E, Menu E, Van Camp B, Vanderkerken K.
    Bull Cancer 95 (3), 301-13, 2008.
    Abstract.

  • Extravasation and homing mechanisms in multiple myeloma..
    Vanden Broek I, Vanderkerken K, Van Camp B, Van Riet I.
    Clin Exp Metastasis ([Epub ahead of print Oct 19]), , 2007.
    Abstract.

  • Tumor-stroma-interacties in multipel myeloom..
    Vanden Broek I, Van Camp B, Schots R, Vanderkerken K, Van Riet I.
    Nederlands Tijdschrift voor Hematologie 4 (7), 283-9, 2007.
    Abstract.

  • De Bijdrage van muismodellen bij studies naar Multiple Myeloom.
    Vanderkerken K, Van Valckenborgh E, Menu E, De Raeve H, Van Riet I, Schots R, Caers J, Van Camp B.
    Nederlands Tijdschrift voor Hematologie 4 (4), 139-43, 2007.
    Abstract.

  • Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: Beneficial effects on tumor growth, angiogenesis, bone disease and survival..
    Menu E, Jernberg-Wiklund H, De Raeve H, De Leenheer E, Coulton L, Gallagher O, Van Valckenborgh E, Larsson O, Axelson M, Nilsson K, Van Camp B, Croucher P, Vanderkerken K.
    Int J Cancer 121 (8), 1857-61, 2007.
    Abstract.

  • Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma..
    Vanderkerken K, Medicherla S, Coulton L, De Raeve H, Willems A, Lawson M, Van Camp B, Protter AA, Higgins LS, Menu E, Croucher PI.
    Cancer Res 67 (10), 4572-7, 2007.
    Abstract.

  • Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells..
    Caers J, Deleu S, Belaid Z, De Raeve H, Van Valckenborgh E, De Bruyne E, Defresne MP, Van Riet I, Van Camp B, Vanderkerken K.
    Leukemia 21 (7), 1580-4, 2007.
    Abstract.

  • Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo..
    Edwards CM, Mueller G, Roelofs AJ, Chantry A, Perry M, Russell RG, Van Camp B, Guyon-Gellin Y, Niesor EJ, Bentzen CL, Vanderkerken K, Croucher PI.
    Int. J Cancer 120 (8), 1657-63, 2007.
    Abstract.

  • An Osteoprotegerin-Like Peptidomimetic Inhibits Osteoclastic Bone Resorption and Osteolytic Bone Disease in Myeloma.
    Heath DJ, Vanderkerken K, Cheng X, Gallagher O, Prideaux M, Murali R, Croucher PI.
    Cancer Res 67, 202-208, 2007.
    Abstract.

  • Immunomodulatory drugs as a therapy for multiple myeloma.
    De Raeve H, Vanderkerken K.
    Curr Pharm Biotechnol. 7 (6), 415-421, 2006.
    Abstract.

  • Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model.
    Menu E, De Leenheer E, De Raeve H, Coulton L, Imanishi T, Miyashita K, Van Valckenborgh E, Van Riet I, Van Camp B, Horuk R, Croucher P, Vanderkerken K.
    Clin Exp Metastasis 23 (05/06/07), 291-300, 2006.
    Abstract.

  • Ac-SDKP: linking cardiac remodeling to hematological malignancies.
    Caers J, Vanderkerken K.
    Leuk Lymphoma 47 (9), 1732-1733, 2006.

  • Endothelial cell-driven regulation of CD9 or motility-related protein-1 expression in multiple myeloma cells within the murine 5T33MM model and myeloma patients.
    De Bruyne E, Andersen TL, De Raeve H, Van Valckenborgh E, Caers J, Van Camp B, Delaisse JM, Van Riet I, Vanderkerken K.
    Leukemia 20 (10), 1870-1879, 2006.
    Abstract.

  • The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model.
    Menu, E, Asosingh, K,Indraccolo, S, De Raeve, H, Van Riet, I, Van Valckenborgh, E, Vande Broek, I, Fuji, N, Tamamura, H, Van Camp, B, Vanderkerken, K.
    Haematologica 91, 605-612, 2006.
    Abstract.

  • Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival.
    Van de Broek, I, Leleu, X, Schots, R, Facon, T, Vanderkerken, K, Van Camp, B, Van Riet, I.
    Haematologica 91 (2), 200-6, 2006.
    Abstract.

  • The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model.
    Caers, J, Gunthert, U, De Raeve, H, Van Valckenborgh, E, Menu, E, Van Riet, I, Van Camp, B, Vanderkerken, K.
    Br J Haematol 132 (4), 469-77, 2006.
    Abstract.

  • IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells.
    Stromberg, T, Ekman, S, Girnita, L, Dimberg, LY, Larsson, O, Axelson, M, Lennartsson, J, Hellman, U, Carlson, K, Osterborg, A, Vanderkerken, K, Nilsson, K, Jernberg-Wiklund, H.
    Blood 107 (2), 669-78, 2006.
    Abstract.

  • Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model.
    Menu, E, Jernberg-Wiklund, H, Stromberg, T, De Raeve, H, Girnita, L, Larsson, O, Axelson, M, Asosingh, K, Nilsson, K, Van Camp, B, Vanderkerken, K.
    Blood 107 (2), 655-60, 2006.
    Abstract.

  • The role of the bone marrow microenvironment in multiple myeloma.
    De Raeve, HR, Vanderkerken, K.
    Histol Histopathol 20 (4), 1227-50, 2005.
    Abstract.

  • Targeting an MMP-9-activated prodrug to multiple myeloma-diseased bone marrow: a proof of principle in the 5T33MM mouse model.
    Van Valckenborgh, E, Mincher, D, Di Salvo, A, Van Riet, I, Young, L, Van Camp, B, Vanderkerken, K.
    Leukemia 19 (9), 1628-33, 2005.
    Abstract.

  • The 5T2MM murine model of multiple myeloma: maintenance and analysis.
    Vanderkerken, K, Asosingh, K, Willems, A, De Raeve, H, Couck, P, Gorus, F, Croucher, P, Van Camp, B.
    Methods Mol Med 113, 191-205, 2005.
    Abstract.

  • Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression.
    Asosingh, K, De Raeve, H, de Ridder, M, Storme, GA, Willems, A, Van Riet, I, Van Camp, B, Vanderkerken, K.
    Haematologica 90 (6), 810-7, 2005.
    Abstract.

  • Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model.
    Van Valckenborgh, E, Croucher, PI, De Raeve, H, Carron, C, De Leenheer, E, Blacher, S, Devy, L, Noel, A, De Bruyne, E, Asosingh, K, Van Riet, I, Van Camp, B, Vanderkerken, K.
    Am J Pathol 165 (3), 869-78, 2004.
    Abstract.

  • Myeloma cells (5TMM) and their interactions with the marrow microenvironment.
    Menu, E, Asosingh, K, Van Riet, I, Croucher, P, Van Camp, B, Vanderkerken, K.
    Blood Cells Mol Dis 33 (2), 111-9, 2004.
    Abstract.

  • Evidence of a role for RANKL in the development of myeloma bone disease.
    De Leenheer, E, Mueller, GS, Vanderkerken, K, Croucher, PI.
    Curr Opin Pharmacol 4 (4), 340-6, 2004.
    Abstract.

  • Part of the multiple myeloma-associated microvessels is functionally connected to the systemic circulation: a study in the murine 5T33MM model.
    De Raeve, HR, Asosingh, K, Wisse, E, Van Camp, B, Van Marck, E, Vanderkerken, K.
    Virchows Arch 445 (4), 389-95, 2004.
    Abstract.

  • Angiogenesis and the role of bone marrow endothelial cells in haematological malignancies.
    De Raeve, H, Van Marck, E, Van Camp, B, Vanderkerken, K.
    Histol Histopathol 19 (3), 935-50, 2004.
    Abstract.

  • Microvessel density, endothelial-cell proliferation and carbonic anhydrase IX expression in haematological malignancies, bone-marrow metastases and monoclonal gammopathy of undetermined significance.
    De Raeve, HR, Vermeulen, PB, Vanderkerken, K, Harris, AL, Van Marck, E.
    Virchows Arch 445 (1), 27-35, 2004.
    Abstract.

  • Myeloma cells (5TMM) and their interactions with the marrow microenvironment.
    Menu, E, Asosingh, K, Van Riet, I, Croucher, P, Van Camp, B, Vanderkerken, K.
    Blood Cells Mol Dis 33 (2), 111-9, 2004.
    Abstract.

  • Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model.
    Menu, E, Kooijman, R, Van Valckenborgh, E, Asosingh, K, Bakkus, M, Van Camp, B, Vanderkerken, K.
    Br J Cancer 90 (5), 1076-83, 2004.
    Abstract.

  • Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model.
    Van Valckenborgh, E, Croucher, PI, De Raeve, H, Carron, C, De Leenheer, E, Blacher, S, Devy, L, Noel, A, De Bruyne, E, Asosingh, K, Van Riet, I, Van Camp, B, Vanderkerken, K.
    Am J Pathol 165 (3), 869-78, 2004.
    Abstract.

  • Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor.
    Vande Broek, I, Asosingh, K, Allegaert, V, Leleu, X, Facon, T, Vanderkerken, K, Van Camp, B, Van Riet, I.
    Leukemia 18 (5), 976-82, 2004.
    Abstract.

  • Migration, adhesion and differentiation of malignant plasma cells in the 5T murine model of myeloma..
    Asosingh K.
    Verh K Acad Geneeskd Belg , , 2003.

  • Delayed in vivo disease progression is associated with high proportions of CD45+ myeloma cells in the 5T2MM murine model.
    Asosingh, K, Willems, A, Van Riet, I, Van Camp, B, Vanderkerken, K.
    Cancer Res 63 (12), 3019-20, 2003.
    Abstract.

  • Selective in vivo growth of lymphocyte function-associated antigen-1-positive murine myeloma cells. Involvement of function-associated antigen-1-mediated homotypic cell-cell adhesion.
    Asosingh, K, Vankerkhove, V, Van Riet, I, Van Camp, B, Vanderkerken, K.
    Exp Hematol 31 (1), 48-55, 2003.
    Abstract.

  • Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis.
    Asosingh, K, De Raeve, H, Van Riet, I, Van Camp, B, Vanderkerken, K.
    Blood 101 (8), 3136-41, 2003.
    Abstract.

  • Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
    Croucher, PI, De Hendrik, R, Perry, MJ, Hijzen, A, Shipman, CM, Lippitt, J, Green, J, Van Marck, E, Van Camp, B, Vanderkerken, K.
    J Bone Miner Res 18 (3), 482-92, 2003.
    Abstract.

  • Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
    Croucher, PI, Shipman, CM, Van Camp, B, Vanderkerken, K.
    Cancer 97 (3 Suppl), 818-24, 2003.
    Abstract.

  • Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3.
    Vande Broek, I, Asosingh, K, Vanderkerken, K, Straetmans, N, Van Camp, B, Van Riet, I.
    Br J Cancer 88 (6), 855-62, 2003.
    Abstract.

  • Multiple myeloma biology: lessons from the 5TMM models.
    Vanderkerken, K, Asosingh, K, Croucher, P, Van Camp, B.
    Immunol Rev 194, 196-206, 2003.
    Abstract.

  • Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
    Vanderkerken, K, De Leenheer, E, Shipman, C, Asosingh, K, Willems, A, Van Camp, B, Croucher, P.
    Cancer Res 63 (2), 287-9, 2003.
    Abstract.

  • Myeloma clonotypic B cells are hampered in their ability to undergo B-cell differentiation in vitro.
    Guikema JE, Vellenga E, Bakkus MH, Bos NA.
    Br J Haematol. 119 (1), 54-61, 2002.

  • Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine models of myeloma.
    Asosingh, K, Menu, E, Van Valckenborgh, E, Vande Broek, I, Van Riet, I, Van Camp, B, Vanderkerken, K.
    Clin Exp Metastasis 19 (7), 583-91, 2002.
    Abstract.

  • The F-actin content of multiple myeloma cells as a measure of their migration.
    Menu, E, Braet, F, Timmers, M, Van Riet, I, Van Camp, B, Vanderkerken, K.
    Ann N Y Acad Sci 973, 124-36, 2002.
    Abstract.

  • Upregulation of matrix metalloproteinase-9 in murine 5T33 multiple myeloma cells by interaction with bone marrow endothelial cells.
    Van Valckenborgh, E, Bakkus, M, Munaut, C, Noel, A, St Pierre, Y, Asosingh, K, Van Riet, I, Van Camp, B, Vanderkerken, K.
    Int J Cancer 101 (6), 512-8, 2002.
    Abstract.

  • Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo.
    Van Valckenborgh, E, De Raeve, H, Devy, L, Blacher, S, Munaut, C, Noel, A, Van Marck, E, Van Riet, I, Van Camp, B, Vanderkerken, K.
    Br J Cancer 86 (5), 796-802, 2002.
    Abstract.

  • Multiple myeloma, a model for fundamental and clinical research.
    Vande Broek, I, Asosingh, K, Vanderkerken, K, Van Riet, I, Van Camp, B.
    Verh K Acad Geneeskd Belg 64 (4), 261-84; discussion 284-6, 2002.
    Abstract.

  • Extramedullary plasmacytoma of the cavernous sinus.
    Vande Broek, I, Stadnik, T, Meurs, A, Maes, J, Van Camp, B, Schots, R.
    Leuk Lymphoma 43 (8), 1691-3, 2002.
    Abstract.

  • Monocyte chemoattractant protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T multiple myeloma cells.
    Vanderkerken, K, Vande Broek, I, Eizirik, DL, Van Valckenborgh, E, Asosingh, K, Van Riet, I, Van Camp, B.
    Clin Exp Metastasis 19 (1), 87-90, 2002.
    Abstract.

  • A unique pathway in the homing of murine multiple myeloma cells: CD44v10 mediates binding to bone marrow endothelium.
    Asosingh, K, Gunthert, U, De Raeve, H, Van Riet, I, Van Camp, B, Vanderkerken, K.
    Cancer Res 61 (7), 2862-5, 2001.
    Abstract.

  • In vivo homing and differentiation characteristics of mature (CD45-) and immature (CD45+) 5T multiple myeloma cells.
    Asosingh, K, De Raeve, H, Croucher, P, Goes, E, Van Riet, I, Van Camp, B, Vanderkerken, K.
    Exp Hematol 29 (1), 77-84, 2001.
    Abstract.

  • Myeloma isotype-switch variants in the murine 5T myeloma model: evidence that myeloma IgM and IgA expressing subclones can originate from the IgG expressing tumour.
    Bakkus, MH, Asosingh, K, Vanderkerken, K, Thielemans, K, Hagemeijer, A, De Raeve, H, Van Camp, B.
    Leukemia 15 (7), 1127-32, 2001.
    Abstract.

  • Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
    Croucher, PI, Shipman, CM, Lippitt, J, Perry, M, Asosingh, K, Hijzen, A, Brabbs, AC, van Beek, EJ, Holen, I, Skerry, TM, Dunstan, CR, Russell, GR, Van Camp, B, Vanderkerken, K.
    Blood 98 (13), 3534-40, 2001.
    Abstract.

  • Laminin-1-induced migration of multiple myeloma cells involves the high-affinity 67 kD laminin receptor.
    Vande Broek, I, Vanderkerken, K, De Greef, C, Asosingh, K, Straetmans, N, Van Camp, B, Van Riet, I.
    Br J Cancer 85 (9), 1387-95, 2001.
    Abstract.

  • The 5TMM series: a useful in vivo mouse model of human multiple myeloma.
    Asosingh, K, Radl, J, Van Riet, I, Van Camp, B, Vanderkerken, K.
    Hematol J 1 (5), 351-6, 2000.

  • In vivo induction of insulin-like growth factor-I receptor and CD44v6 confers homing and adhesion to murine multiple myeloma cells.
    Asosingh, K, Gunthert, U, Bakkus, MH, De Raeve, H, Goes, E, Van Riet, I, Van Camp, B, Vanderkerken, K.
    Cancer Res 60 (11), 3096-104, 2000.
    Abstract.

  • Clonally related IgA- and IgE-secreting plasma cells in a myeloma patient.
    Bakkus, MH, Schots, R, Gomez La Fuente, PB, Van Riet, I, Thielemans, K, De Waele, M, Van Camp, B.
    Eur J Haematol 65 (5), 348-55, 2000.
    Abstract.

  • Bone sialoprotein mRNA and protein expression in human multiple myeloma cell lines and patients.
    Bellahcene, A, Van Riet, I, de Greef, C, Antoine, N, Young, MF, Van Camp, B, Castronovo, V.
    Br J Haematol 111 (4), 1118-21, 2000.
    Abstract.

  • Bisphosphonates--mechanisms of action in multiple myeloma.
    Shipman, CM, Rogers, MJ, Vanderkerken, K, Van Camp, B, Graham, R, Russell, G, Croucher, PI.
    Acta Oncol 39 (7), 829-35, 2000.
    Abstract.

  • The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
    Shipman, CM, Vanderkerken, K, Rogers, MJ, Lippitt, JM, Asosingh, K, Hughes, DE, Van Camp, B, Russell, RG, Croucher, PI.
    Br J Haematol 111 (1), 283-6, 2000.
    Abstract.

  • Homing of the myeloma cell clone.
    Vanderkerken, K, Van Camp, B, De Greef, C, Vande Broek, I, Asosingh, K, Van Riet, I.
    Acta Oncol 39 (7), 771-6, 2000.
    Abstract.

  • Late and localized extramedullary relapse of a light chain kappa myeloma after syngeneic bone marrow transplantation..
    Trullemans F, Schots R, Storme G, Van Camp B.
    Bone Marrow Transplant. 25 (1), 115-7, 2000.

  • Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KalwRij mouse.
    Vanderkerken, K, De Greef, C, Asosingh, K, Arteta, B, De Veerman, M, Vande Broek, I, Van Riet, I, Kobayashi, M, Smedsrod, B, Van Camp, B.
    Br J Cancer 82 (4), 953-9, 2000.
    Abstract.

  • Use of quantitative ASO-PCR to predict relapse in multiple myeloma.
    Cooke F, Bakkus M, Thielemans K, Pico JL, Apperley JF, Samson D.
    Br J Haematol 105 (1), 317-9, 1999.

  • Homing mechanisms of myeloma cells.
    Van Riet I.
    Pathol Biol (Paris) 47 (2), 98-108, 1999.

  • Ig gene sequences in the study of clonality..
    Bakkus MH.
    Pathol Biol (Paris) 47 (2), 128-47, 1999.

  • Genes encoding tumor-specific antigens are expressed in human myeloma cells.
    van Baren N, Brasseur F, Godelaine D, Hames G, Ferrant A, Lehmann F, Andre M, Ravoet C, Doyen C, Spagnoli GC, Bakkus M, Thielemans K, Boon T.
    Blood 94 (4), 1156-64, 1999.

  • Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial..
    Facon T, Harousseau JL, Maloisel F, Attal M, Odriozola J, Alegre A, Schroyens W, Hulin C, Schots R, Marin P, Guilhot F, Granena A, De Waele M, Pigneux A, Meresse V, Clark P, Reiffers J.
    Blood. 94 (4), 1218-25., 1999.

  • Multiple myeloma related cells in patients undergoing autologous peripheral blood stem cell transplantation..
    Guikema JE, Vellenga E, Veeneman JM, Hovenga S, Bakkus MH, Klip H, Bos NA.
    Br J Haematol 104 (4), 748-54, 1999.

  • Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) DNA sequences are absent in leukapheresis products and ex vivo expanded CD34+ cells from multiple myeloma patients.
    De Greef, C, Van De Voorde, W, Bakkus, M, Corthals, J, Heirman, C, Schots, R, Lacor, P, Van Camp, B, Van Riet, I.
    Br J Haematol 106 (4), 1033-6, 1999.
    Abstract.

  • Multiple myeloma. A model of nature.
    Van Camp, B, Fenaux, P.
    Pathol Biol (Paris) 47 (2), 87-8, 1999.

  • Insulin-like growth factor-1 acts as a chemoattractant factor for 5T2 multiple myeloma cells.
    Vanderkerken, K, Asosingh, K, Braet, F, Van Riet, I, Van Camp, B.
    Blood 93 (1), 235-41, 1999.
    Abstract.

  • Differential gene expression of the neural cell adhesion molecule (N-CAM) in a panel of multiple myeloma cell lines.
    De Greef, C, Van Riet, I, Bakkus, MH, Van Camp, B.
    Leukemia 12 (1), 86-93, 1998.
    Abstract.

  • Homing mechanisms in the biology of multiple myeloma.
    Van Camp, B, Van Riet, I.
    Verh K Acad Geneeskd Belg 60 (3), 163-94, 1998.
    Abstract.

  • Immunoglobulin VH gene sequence analysis of spontaneous murine immunoglobulin-secreting B-cell tumours with clinical features of human disease.
    Zhu D, van Arkel C, King CA, Meirvenne SV, de Greef C, Thielemans K, Radl J, Stevenson FK.
    Immunology 93 (2), 162-70, 1998.

  • Homing behaviour of the malignant cell clone in multiple myeloma.
    Van Riet, I, Vanderkerken, K, de Greef, C, Van Camp, B.
    Med Oncol 15 (3), 154-64, 1998.
    Abstract.

  • Immunoglobulins D and M multiple myeloma variants are heavily mutated.
    Juge-Morineau, N, Heirman, C, Bakkus, M, Van Camp, B, Malfait, R, Harousseau, JL, Thielemans, K, Bataille, R.
    Clin Cancer Res 3 (12 Pt 1), 2501-6, 1997.
    Abstract.

  • Persistence of residual tumour cells after cytokine-mediated ex vivo expansion of mobilized CD34+ blood cells in multiple myeloma.
    Van Riet, I, Juge-Morineau, N, Schots, R, De Waele, M, De Greef, C, Thielemans, K, Van Camp, B, Bakkus, M.
    Br J Haematol 96 (2), 403-11, 1997.
    Abstract.

  • Establishment and characterization of a human stroma-dependent myeloma cell line (MM5.1) and its stroma-independent variant (MM5.2).
    Van Riet, I, De Greef, C, Aharchi, F, Woischwill, C, De Waele, M, Bakkus, M, Lacor, P, Schots, R, Van Camp, B.
    Leukemia 11 (2), 284-93, 1997.
    Abstract.

  • Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse.
    Vanderkerken, K, De Raeve, H, Goes, E, Van Meirvenne, S, Radl, J, Van Riet, I, Thielemans, K, Van Camp, B.
    Br J Cancer 76 (4), 451-60, 1997.
    Abstract.

  • Adhesive interactions between tumour cells and bone marrow stromal elements in human multiple myeloma.
    Faid, L, Van Riet, I, De Waele, M, Facon, T, Schots, R, Lacor, P, Van Camp, B.
    Eur J Haematol 57 (5), 349-58, 1996.
    Abstract.

  • Detection of minimal residual disease in multiple myeloma and acute leukaemia..
    Bakkus MH, Juge-Morineau N, van der Werff ten Bosch JE.
    Med Oncol. 13 (2), 121-31, 1996.

  • Follow-up of bone lesions in an experimental multiple myeloma mouse model: description of an in vivo technique using radiography dedicated for mammography.
    Vanderkerken, K, Goes, E, De Raeve, H, Radl, J, Van Camp, B.
    Br J Cancer 73 (12), 1463-5, 1996.
    Abstract.

  • The clonogenic precursor cell in multiple myeloma.
    Bakkus, MH, Van Riet, I, De Greef, C, Van Camp, B, Thielemans, K.
    Leuk Lymphoma 18 (03/04/06), 221-9, 1995.
    Abstract.

  • Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after.
    Pellat-Deceunynk, C, Amiot, M, Bataille, R, Van Riet, I, Van Camp, B, Omede, P, Boccadoro, M.
    Blood 86 (10), 4001-2, 1995.

  • Homing mechanisms in the etiopathogenesis of multiple myeloma.
    Van Riet, I, Bakkus, M, De Greef, C, Faid, L, Van Camp, B.
    Stem Cells 13 Suppl 2, 22-7, 1995.
    Abstract.

  • Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell.
    Bakkus, MH, Van Riet, I, Van Camp, B, Thielemans, K.
    Br J Haematol 87 (1), 68-74, 1994.
    Abstract.

  • Production of fibronectin and adherence to fibronectin by human myeloma cell lines.
    van Riet, I, de Greef, C, del Favero, H, Demanet, C, Van Camp, B.
    Br J Haematol 87 (2), 258-65, 1994.
    Abstract.

  • The involvement of adhesion molecules in the biology of multiple myeloma.
    Van Riet, I, Van Camp, B.
    Leuk Lymphoma 9 (6), 441-52, 1993.
    Abstract.

  • Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation.
    Bakkus, MH, Heirman, C, Van Riet, I, Van Camp, B, Thielemans, K.
    Blood 80 (9), 2326-35, 1992.
    Abstract.

  • Monoclonal gammopathy as a model for B-cell differentiation: fromparaproteinto artificial antibodies.
    Bast, EJ, van Camp, B.
    Neth J Med 39 (03/04/06), 209-15, 1991.
    Abstract.

  • Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells.
    Van Riet, I, De Waele, M, Remels, L, Lacor, P, Schots, R, Van Camp, B.
    Br J Haematol 79 (3), 421-7, 1991.
    Abstract.

  • Diagnostic and prognostic value of the MB2 monoclonal antibody in paraffin-embedded bone marrow sections of patients with multiple myeloma and monoclonal gammopathy of undetermined significance.
    Dehou, MF, Schots, R, Lacor, P, Arras, N, Verhavert, P, Kloppel, G, van Camp, B.
    Am J Clin Pathol 94 (3), 287-91, 1990.
    Abstract.

  • Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19).
    Van Camp, B, Durie, BG, Spier, C, De Waele, M, Van Riet, I, Vela, E, Frutiger, Y, Richter, L, Grogan, TM.
    Blood 76 (2), 377-82, 1990.
    Abstract.

  • Detection of monoclonal B lymphocytes in bone marrow and peripheral blood of multiple myeloma patients by immunoglobulin gene rearrangement studies.
    Van Riet, I, Heirman, C, Lacor, P, De Waele, M, Thielemans, K, Van Camp, B.
    Br J Haematol 73 (3), 289-95, 1989.
    Abstract.

  • Phenotypical and functional characterization of the idiotype-positive blood B cells in multiple myeloma.
    Bloem, AC, Chand, MA, van Camp, B, Bast, EJ, Ballieux, RE.
    Scand J Immunol 28 (6), 791-9, 1988.
    Abstract.

  • Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial.
    Ludwig, H, Cortelezzi, A, Scheithauer, W, Van Camp, BG, Kuzmits, R, Fillet, G, Peetermans, M, Polli, E, Flener, R.
    Eur J Cancer Clin Oncol 22 (9), 1111-6, 1986.
    Abstract.

  • Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma.
    Caligaris-Cappio, F, Bergui, L, Tesio, L, Pizzolo, G, Malavasi, F, Chilosi, M, Campana, D, van Camp, B, Janossy, G.
    J Clin Invest 76 (3), 1243-51, 1985.
    Abstract.

  • [Interferon in the treatment of multiple myeloma].
    Kuzmits, R, Ludwig, H, Cortelezzi, A, Van Camp, BG, Polli, E, Flener, R, Scheithauer, W.
    Acta Med Austriaca 12 (5), 135-8, 1985.
    Abstract.

  • Treatment with recombinant interferon-alpha-2C: multiple myeloma and thrombocythaemia in myeloproliferative diseases.
    Ludwig, H, Cortelezzi, A, Van Camp, BG, Polli, E, Scheithauer, W, Kuzmits, R, Linkesch, W, Gisslinger, H, Sinzinger, H, Fritz, E, et al..
    Oncology 42 Suppl 1, 19-25, 1985.
    Abstract.

  • Idiotypic peripheral blood lymphocytes in monoclonal gammopathy.
    Bast, EJ, van Camp, B, Reynaert, P, Wiringa, G, Ballieux, RE.
    Clin Exp Immunol 47 (3), 677-82, 1982.

  • Two monoclonal antibodies (OKIa1 and OKT10) for the study of the final B cell maturation.
    Van Camp, B, Thielemans, C, Dehou, MF, De Mey, J, De Waele, M.
    J Clin Immunol 2 (3 Suppl), 67S-74S, 1982.
    Abstract.

  • Discriminant analysis of parameters referring to the monoclonal cellular event in multiple myeloma and benign monoclonal gammopathy.
    Van Camp, B, Coomans, D, Massart, DL, De Waele, M, Thielemans, C.
    Acta Clin Belg 37 (6), 348-55, 1982.

  • Differentiation between benign and malignant monoclonal gammopathy by the presence of the J chain.
    Bast, EJ, Van Camp, B, Boom, SE, Jaspers, FC, Ballieux, RE.
    Clin Exp Immunol 44 (2), 375-82, 1981.
    Abstract.

  • Studies on the origin of the precursor cells in multiple myeloma, Waldenstrom's macroglobulinaemia and benign monoclonal gammopathy. I Cytoplasmic isotype and idiotype distribution in peripheral blood and bone marrow.
    Van Camp, B, Reynaert, P, Broodtaerts, L.
    Clin Exp Immunol 44 (1), 82-9, 1981.
    Abstract.

  • Immunofluorescence as an aid in the detection and classification of paraproteinaemia.
    Hijmans, W, Schuit, HR, van Nieuwkoop, JA, van Camp, B.
    Ric Clin Lab 10 (1), 17-21, 1980.

  • Surface and cytoplasmic immunoglobulin distribution during treatment of a non-excretory myeloma.
    Van Camp, BV, Lambrecht, A, de Bock, R, Peetermans, M.
    Biomedicine 30 (1), 28-31, 1979.
    Abstract.

  • HLA antigens and homogeneous immunoglobulins.
    Van Camp, BG, Cole, J, Peetermans, ME.
    Clin Immunol Immunopathol 7 (3), 315-8, 1977.

  • [M-components in blood donors in Antwerp. Studies on the incidence and course in 24 donors].
    van Camp, B, Cole, J, Peetermans, ME.
    Acta Clin Belg 31 (4), 203-11, 1976.

 

Back to top

  ©2004-2006 • HEIM • Vrije Universiteit Brussel • Faculteit Geneeskunde & Farmacie • Laarbeeklaan 103 • 1090 Jette • Tel.: (+32)-(0)2-477.44.06 • heim@vub.ac.be